Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Pamiparib with Chemoradiotherapy in Recurrent Head and Neck Cancer
NCT05526924Phase 1Recruiting
- Sponsor
- University of Chicago
- Start
- Mar 2023
- Primary completion
- Jan 2028
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of pamiparib and tislelizumab in head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by University of Chicago. Primary endpoint: Maximum Tolerated Dose/Recommended Phase 2 Dose at 15 months. Started Mar 2023; status: recruiting.
02
Drugs
pamiparibtislelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05526924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526924.